Symptoms in patients on long-term proton pump inhibitors: Prevalence and predictors

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 4, 2009, Pages 431-439

  Raghunath, A S ^a   Hungin, A P S ^a   Mason, J ^a   Jackson, W ^b  

^a DURHAM UNIVERSITY   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIFESTYLE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; STOMACH PROTECTION; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; BREATH TESTS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSPEPSIA; ENGLAND; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROTON PUMP INHIBITORS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 58149310707     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03897.x     Document Type: Article

References (36)

1. Department of Health. Prescription Cost Analysis: England 2002. Department of Health, 2003. Available at: http://www.dh.gov.uk/assetRoot/04/08/ 01/96/04080196.pdf (accessed 25 October 2008).
2. Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005 22 (Suppl. 1 55 63.
3. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998 317 : 452 6.
4. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003 98 : 51 8.
5. Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004 19 : 917 22.
6. Raghunath AS, Hungin AP, Childs S, Wooff D. The prevalence of Helicobacter pylori in gastro-oesophageal reflux disease: a systematic review. BMJ 2003 326 : 736 9.
7. Jakobs R, Riemann JF. cagA-positive Helicobacter pylori strains and gastro-oesophageal reflux disease: still puzzling? Eur J Gastroenterol Hepatol 2004 16 : 635 7.
8. Raghunath AS, Hungin AP, Mason J, Jackson W. Helicobacter pylori eradication in long-term proton pump inhibitor users in primary care: a randomized controlled trial. Aliment Pharmacol Ther 2007 25 : 585 92.
9. Asante MA, Mendall MA, Bland JM, Northfield TC. Determinants of prescribing costs for ulcer-healing drugs and upper gastrointestinal endoscopy in general practice. Eur J Gastroenterol Hepatol 1998 10 : 589 93.
10. Mason J, Hungin AP. Review article: gastro-oesophageal reflux disease - the health economic implications. Aliment Pharmacol Ther 2005 22 (Suppl. 1 20 31.
11. Woodward M, Morrison CE, McColl KE. The prevalence of dyspepsia and use of antisecretory medication in North Glasgow: role of Helicobacter pylori vs. lifestyle factors. Aliment Pharmacol Ther 1999 13 : 1505 9.
12. Harris CM, Dajda R. The scale of repeat prescribing. Br J Gen Pract 1996 46 : 649 53.
13. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999 49 : 451 3.
14. Boath EH, Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients' perspectives. Soc Sci Med 1997 45 : 1571 9.
15. NICE guideline. Dyspepsia: Managing Dyspepsia in Adults in Primary Care. UK : National Guideline Research and Development Unit, University of Newcastle upon Tyne, 2004. Available at: http://www.nice.org.uk (accessed 25 October 2008).
16. Scottish Intercollegiate Guidelines Network. Dyspepsia: A National Clinical Guideline. Scottish Intercollegiate Guidelines Network (SIGN68), 2003. Available at: http://www.sign.ac.uk (accessed 25 October 2008).
17. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman Bea. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996 334 : 1018 22.
18. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of H. pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 16 : 167 80.
19. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999 117 : 11 6.
20. Hurenkamp GJ, Grundmeyer HG, Bindels PJ, Tytgat GN, Van Der Hulst RW. How do primary care physicians use long-term acid suppressant drugs? A population-based analysis of Dutch general practices. J Fam Pract 2002 51 : 241 5.
21. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000 321 : 659 64.
22. Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008 336 : 651 4.
23. Ford AC, Moayyedi P, Jarbol DE, Logan RF, Delaney BC. Meta-analysis: Helicobacter pylori'test and treat' compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther 2008 28 : 534 44.
24. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2003 2 : CD001961.
25. Lassen A, Hallas J, de Muckadell OB. Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study. BMJ 2003 327 : 603.
26. Bast P. Breath Tests from INFAI. INFAI Institute for Biomedical Analyticals and NMR Imaging GmbH. 2002. Available at: http://www.infai- international.com/scripten/iquery.cgi?res=ae12 (accessed 25 October 2008).
27. Heywood PAH. INFAI breath test in general practice. Cleveland Med J 2001 4 : 116 8.
28. Moayyedi P, Duffett S, Braunholtz D, et al. The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. Aliment Pharmacol Ther 1998 12 : 1257 62.
29. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998 33 : 1023 9.
30. Kind P. The EuroQol instrument: an index of health-related quality of life. In : Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia, PA : Lippincott-Raven Publishers, 1996 : 191 201.
31. Wu JC, Chan FK, Wong SK, Lee YT, Leung WK, Sung JJ. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther 2002 16 : 545 52.
32. Raghunath AS, Hungin AP, Wooff D, Childs S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004 20 : 733 44.
33. Loffeld RJ, Werdmuller BF, Kuster JG, Perez-Perez GI, Blaser MJ, Kuipers EJ. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000 62 : 95 9.
34. Wu JC, Sung JJ, Chan FK, et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 14 : 427 32.
35. Warburton-Timms VJ, Charlett A, Valori RM, et al. The significance of cagA(+) Helicobacter pylori in reflux oesophagitis. Gut 2001 49 : 341 6.
36. Brozek JL, Guyatt GH, Heels-Ansdell D, et al. Specific HRQL instruments and symptom scores were more responsive than preference-based generic instruments in patients with GERD 1. J Clin Epidemiol Epub ahead of print 9 July 2008 ]